The approved product is a generic version of Periactin tablets of Merck & Co. Inc.
Strides said the product will be manufactured at its oral dosage facility at Bengaluru and will be marketed by Strides Pharma Inc in the US.
Citing IQVIA data, the company said the US market for Cyproheptadine Hydrochloride tablets USP, 4 mg is approximately USD 20 million.
The company's stock was trading 0.58 per cent higher at Rs 645.60 per scrip on the BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)